Clinical trial NCT00315861: Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
Official title: A Phase I Study of Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Ovarian Cancer
Endometrial Cancer
Cervical Cancer
Lung Cancer
Keywords: ovarian carcinoma
endometrial carcinoma
cervical carcinoma
lung carcinoma
Lead sponsor: SCRI Development Innovations, LLC
Sponsor class: OTHER
Collaborators: name: GlaxoSmithKline
name: Eli Lilly and Company
First posted: 2006-04-19
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Currently, no data exists regarding the safety and tolerability of a combination regimen utilizing weekly topotecan in combination with pemetrexed. Although both drugs are associated with myelosuppression, it is hoped that the utilization of the weekly topotecan dosing schedule will allow the drugs to be easily combined. This phase I trial will evaluate the safety and tolerability of weekly topotecan in combination with pemetrexed in patients with advanced solid tumors.

Detailed description: Three patients will be accrued at each of 5 dose levels. Dose escalation will only proceed if none of the additional 3 patients experience DLT. The highest dose level that generates DLT in 0/3 or 1/6 patients will be the maximum tolerated dose (MTD) or the doses recommended for subsequent studies. A total of 10 patients will be treated at the MTD to further assess the toxicity of the dosing regimen and its suitability for use in subsequent trials. Patients may continue to receive treatment until unacceptable toxicity or disease progression is encountered. Treatment cycles will be repeated every 21 days. The protocol is also designed to enroll an additional 10 patients at the maximum tolerated dose to increase the confidence in the safety and suitability of the doses that are chosen for subsequent studies.

* Topotecan Day 1 and 8
* Pemetrexed Day 1

Eligibility criteria: Inclusion Criteria:

* Histologically proven advanced solid tumors
* Measurable or evaluable disease
* Age ≥ 18 years
* Karnofsky performance status ≥ 80% (ECOG 0 or 1)
* Adequate liver, bone marrow and kidney function

Exclusion Criteria:

* More than 3 prior chemotherapy regimens in the metastatic setting
* Prior treatment with topotecan or pemetrexed
* Clinically significant third space fluid present at the time of treatment
* Unable to interrupt aspirin, other non-steroidal anti-inflammatory drugs
* Inability to take steroid premedications or vitamin supplementation
* The presence of active brain metastases
* Prior radiotherapy within 4 weeks prior to the first day of treatment
* Prior surgery within 3 weeks prior to the first day of treatment
* Prior chemotherapy within 3 weeks prior to the first day of treatment

Primary outcomes:
measure: maximum tolerated doses of drugs in combination
measure: overall toxicity of drug combination
measure: preliminary antitumor activity of drug combination
measure: impact of pemetrexed on topotecan pharmacokinetics
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Tennessee Oncology, PLLC
state: Tennessee
Study officials:
affiliation: SCRI Development Innovations, LLC
name: Howard Burris, MD
role: PRINCIPAL_INVESTIGATOR
References: